







8.00	Registration and breakfast
	
9.00	Welcome Remarks Terry O'Dwyer , Co-CEO, Biotech and Money Neil Darkes , Co-CEO, Biotech and Money
	
	REPORT LAUNCH: LIFESCIENCE INVESTMENT IN THE UK: FACT AND FICTION
9.05	<p>HOW CAN THE UK HARNESS THE OPPORTUNITY TO THRIVE?</p> <ul style="list-style-type: none"> • Can the UK build a life science sector to rival that of the US? How? What are the catalysts and inhibitors? • How can the lack of sources of capital and shortage of knowledgeable investors be addressed? • How do you keep generalist investors interested in Biotech? • What is the role of big pharma in capitalizing on the opportunity in the UK? • How can incentives for investment be increased and the funding environment improved? <p>Over 25 of the UK's leading healthcare company CEO's, leading investors, banks and stakeholders such as Rt. Hon. George Freeman, Neil Woodford, Imperial Innovations, London Stock Exchange and the BIA have come together to bring you a groundbreaking report that illustrates the fundamental truths about investing in the UK. Hard facts, sound bite data and in depth case studies will debunk the myths about healthcare investment in this country. This session will feature some of the cornerstone players in the report to discuss and debate the findings and highlights.</p> <p>Moderator: David MacMurchy, Partner, Consumer Products, Retail and Life Science Leader and Head of Life Sciences, EY (C) Darrin Disley, CEO, Horizon Discovery (C) Peter George, CEO, Clinigen (C) Elizabeth Klein, Founder, Klein-Edmonds Associates (Co-author of the report) (C) Russ Cummings, CEO, Imperial Innovations (C) Cathrin Petty, MD and Co-Head of European Healthcare Banking, JPMorgan (C)</p>
	KEYNOTE PANEL: THE VICES AND VIRTUES OF PATIENT CAPITAL
10:05	<ul style="list-style-type: none"> • Will the patient capital approach pay off? Why? • What business models are being backed and why? • What are the risk profiles being considered and why?

	<ul style="list-style-type: none"> • How much of the funds are earmarked for UK, or are funds invested opportunistically? • What are the strategies and drivers underpinning investment decisions? • Is there enough critical mass of patient investors now to feed the supply of innovation coming out of the UK? <p>Moderator: Sam Fazeli, Senior Analyst and European Head, Bloomberg Intelligence (C) Nigel Pitchford, CIO, Imperial Innovations (C) Peter Dines, Head of Life Sciences, Mercia Fund Management (C) Robert Tansley, Investment Director, Cambridge Innovation Capital (C) Sam Williams, Head, Biotech, IP Group (C)</p>		
	FIRE SIDE CHATS: UK-US MONEY FLOW		
10:45	<p>As the UK finally starts to catch up with US in biotech investment, with capital funding more than doubling last year here in the UK, we take the opportunity to hold two fireside chats with a prominent UK serial entrepreneur and US investment firm to provide their take on the emerging dynamic and to hear about emerging investment preferences.</p> <p>Moderator: Peter Evans, Leisure and Pharmaceutical Reporter, The Sunday Times (C) Jim Mellon, Serial Entrepreneur and Founder, Mann Bioinvest (C)</p>		
11.15	Morning coffee		
	 		
	EARLY-STAGE	GROWTH-STAGE	HEALTHEx CEO / CFO FORUM
11.45	<p>Is technology transfer and translation working in life sciences?</p> <ul style="list-style-type: none"> • Is technology transfer broken? What needs fixing, and how will it be done? • What are the real truths about valuing IP and risk sharing? • How can the eco system in the midlands, North and Scotland be leveraged and strengthened? 	<p>How to fund development and growth stage companies</p> <ul style="list-style-type: none"> • Understanding different approaches to company creation and funding: What works, when and why? • Is the traditional VC model in danger of being overtaken by patient capital? • How is the role of the CVC changing? • The role of private equity, hedge funds and family offices in funding life sciences 	<p>HealthEx is sponsored by EY, Nasdaq, Covington and Burling and Panmure Gordon</p> <p>HealthEx London is a closed door, off the record, invite only forum, where CEOs, CFOs and Chairmen of listed life science and healthcare companies debate ideas and strategies for growth and partnerships, investor engagement and education; problem solve fundraising and capital challenges and come together to share ideas on how to promote and cultivate a strong and vibrant environment for life science investment.</p>

	<ul style="list-style-type: none"> How can TTO's add the most value for entrepreneurs, and how can they collaborate strategically with industry? How is pharma's approach to translation and accessing of innovative medicines changing? <p>Moderator: Malcolm Skingle, Director, Academic Liaison, GSK (C) Adam Stoten, Head of Technology Transfer, Life Sciences. Isis Innovation (C) Tony Hickson, Managing Director, Tech Transfer, Imperial Innovations (C) Iain Thomas, Head of Life Sciences, Cambridge Enterprise (C) Mike Capaldi, CEO, SUNERGOS Innovations (C) Steven Walls, Partner, Gill Jennings & Every LLP (C)</p>	<ul style="list-style-type: none"> How is the current financing environment shaping strategies? <p>Moderator: Joe Pillman, Partner, Wilmer Hale (C) Deborah Harland, Partner, SR One (C) Hakan Goker, Partner, MS Ventures (C) Genghis Lloyd-Harris, Partner, Abingworth (C) Shahzad Malik, General Partner, Advent Life Sciences (C) Carol Routledge, Venture Partner, SV Life Sciences (C) Sinclair Dunlop, Managing Partner, Epidarex Capital (C)</p>	<p>How to improve investor appetite for the sector</p> <ul style="list-style-type: none"> How do we get more generalist investors educated and interested? How can the dearth of specialist investors and supporting analyst community in Europe be addressed? How to celebrate success stories and communicate them ? AIM vs Full list is there a difference for investors? What does a successful financing look like? How will capital raising strategies change in 2016? <p>Moderators: Freddy Crossley, Partner, Corporate Finance, Panmure Gordon & Co. (C) Julie Simmonds, Director, Equity Research, Panmure Gordon (C)</p>
12.25	<p>Crossing the valley of death: funding, financing and strategy</p> <ul style="list-style-type: none"> What is the current state of the market for early stage funding? Beyond bootstrapping, competitions and grants: What are some of the offbeat approaches to bridging the gap? Debt financing and creative financing options: when are they appropriate? How to position the company to raise capital, how to allocate equity and how to think about vesting criteria The role of new asset class of investors in early stage funding <p>Moderator: Sue Staunton, Partner, James Cowper Kreston (C) Richard Seabrook, Head of Business Development, Innovations, Wellcome Trust (C) Francois Martelet, CEO, NetScientific (C) Ayal Ronen, Vice President, Freemind (C) James Shaw, Co-Founder, JAG Shaw Baker</p>	<p>Licensing, asset acquisitions and innovative deal structures</p> <ul style="list-style-type: none"> What are some of the most innovative deal structures we've seen? Why have these trends developed? What is the current thinking behind recent valuations? Does this need to change? What needs to change? What do you see as the major internal and external factors influencing agreements Is there the right balance between up-front payments and milestones in today's deal making? What are the challenges you see being faced by executives of life science companies both large and small? <p>Moderator: Lisa Urquhart, Editor, EP Vantage (C) Keith Blundy, CEO, Cancer Research</p>	<p>US vs Uk listings? How and where should your tap public markets?</p> <ul style="list-style-type: none"> How should current trends in listing / placements inform your capital strategy? Comparing and contrasting US with UK listings and placements and and key success factors How to ensure listings and placements are value creative Considerations in tapping US vs. UK markets <ul style="list-style-type: none"> What should CEOs / CFOs be aware of in today's climate? <p>Moderator: Adam Kostyal, EVP EMEA, Nasdaq (C) Asaf Homossany, Managing Director, EMEA, Nasdaq (C)</p>

	<p>(C) Goncalo de Vasconcelos, CEO, Syndicate Room (C)</p>	<p>Technology (C) Eva-Lotta Allan, CBO, Immunocore (C) John Rountree, Partner, Novasecta Ltd. (C) Timothy Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca (C) Stewart Kay, Director, Transactions, GSK (C)</p>	
13.05	Networking Lunch		
			
14.05	<p>How to fly with Angels</p> <ul style="list-style-type: none"> What do angels and high net worths look for in a life science start up? How do you win them over? How to pitch to an angel Ensuring mutually beneficial incentives, terms and deal structures <p>Moderator: Simon Kerry, CEO, Karus Therapeutics (C) Will West, CEO, CellCentric (C) Andy Richards CBE, Serial Biotechnology Entrepreneur and Business Angel (C) Anthony Clarke, CEO, Angel Capital Group (C) Eileen Modral, Investment Network Manager, Oxford Investment Opportunity Network and Oxford Early Investments (C)</p>	<p>Tales from the road: successful private financing deals</p> <p>Executives from recent private funding rounds share their tips, tricks, war stories and key success factors from recent raises. Plus comment on:</p> <ul style="list-style-type: none"> Viewpoints on investment momentum and investor sources How liquid is money flow right now Have investor expectations changed in the last 12 months What can we expect from the companies themselves <p>Moderator: Makiko Kitamura, European Health and Science Reporter, Bloomberg News (C) John Beadle, CEO, PsiOxus Therapeutics (C) Jonathan Allis, CEO, Blue Earth Diagnostics (C)</p>	<p>Creating and Unlocking Value: How and where will you grow?</p> <ul style="list-style-type: none"> How should current trends in M&A and licensing inform your growth strategy? Comparing and contrasting M&A strategies and key success factors How to ensure M&A is value creative How can capital be used more efficiently allowing companies' resources to be deployed in ways that create the most value? Considerations in moving into new markets vs expanding your share in existing markets What should CEO's focus on when searching for collaborations or partnerships? <p>Moderators: Jamie Heath, Head of Life Sciences Transaction Advisory, Europe, Middle East, Africa and India, EY (C) Leo Gribben, Partner, Life Sciences Transaction Advisory, EY (C)</p>


		David Fellows , CEO, NightstaRx (C) Kevin Johnson , Venture Partner, Index Ventures (C) Maina Bhaman , Director of Healthcare Investments, Imperial Innovations (C)	
14.45	<p>How to realise the true value of industry-academia collaboration</p> <ul style="list-style-type: none"> • What is the most efficient model for how pharma and academia can collaborate? • Understanding the drivers, desires and deal breakers of both industry and academia in early stage collaborations • Understanding and developing new models of commercialising university IP • Open innovation: what are the motivators for pharma, and where will it lead? <p>Moderator: John Hodgson, Data Editor, SCRIP (C) Tim Luker, Senior VP, External R&D, Lilly (C) Mene Pangalos, Executive Vice President, Innovative Medicines and Early Development, AstraZeneca (C) Paul-Peter Tak, Chief Immunology Officer & SVP R&D Pipeline, GSK (C) Juan Carlos Lopez, Head, Academic Relations and Collaborations, Roche (C) Harren Jhoti, President and CEO, Astex Therapeutics (C)</p>	<p>Achieving success on UK public markets</p> <p>CEOs from recent public raises share their tips, tricks, war stories and key success factors. Plus comment on:</p> <ul style="list-style-type: none"> • What forces have been driving primary and secondary public offerings, and are they here to stay? • Will high valuations and a strong capital market continue? • What impact is the mainstream investor appeal of Biotech having on the sector? • What external factors will impact market momentum? • What can we expect from the companies themselves? <p>Moderator: Gary Green, Corporate partner and Head of Equity Capital Markets, CMS Cameron McKenna (C) Dr Stephen Franklin, CEO, Evgen Pharma (C) Martin Whitaker, CEO, Diurnal Group (C) Dr Markku Jalkanen, CEO, Faron Pharmaceuticals (C) Paul Cuddon, Director, Healthcare Equity Research, Numis Securities (C)</p>	<p>Strategic transactions to realise value</p> <ul style="list-style-type: none"> • When to realise value; • Bringing about the deal; • Deal alternatives: licensing, partnerships and joint ventures, M&A, and hybrid deals; • What works and what doesn't: and why? <p>Moderators: Paul Claydon, Partner and Head, Corporate Practice, Europe, Covington and Burling LLP (C) James Halstead, Partner, Corporate Practice, Europe, Covington and Burling LLP (C)</p>
15.25	Afternoon refreshments		
	CAPITAL MARKETS		



15.55	<ul style="list-style-type: none"> • How long will current market conditions last? Will the IPO window remain open? • What have recent stories taught us? • Creative strategies to raise capital and tap the market (primary and secondary's) • Assessing the current level of investor enthusiasm for life science stocks • How to appeal to the modern generalist investor – can life science become mainstream? <p>Moderator: John Hodgson, Data Editor, SCRIP (C) Adam Kostyal, EVP EMEA, Nasdaq (C) Carl Sterritt, CEO, Shield Therapeutics (C) Paul Tomasic, Managing Director, Healthcare EMEA, RBC Capital Markets (C)</p>
	M&A, COMPANY GROWTH AND EXITS
16.35	<ul style="list-style-type: none"> • What is the current industry appetite for M&A? • What are some of the more creative M&A strategies you have witnessed? • What are some of the common due diligence and transactional risk management challenges that exist in this sector? • What advice would you give to acquirers on identifying targets and unlocking post-deal synergies? • How do you see M&A activity in the biotech and pharmaceutical sector progressing in 2016? <p>Moderator: Simon Amies, Partner, Corporate Practice, Europe, Covington and Burling LLP (C) John Burt, CEO, Abzena (C) Andrea Ponti, Executive Partner and Founder, GHO Capital (C) Matthew Foy, Partner, SR One (C) Sander Slootweg, Managing Partner, Forbion Capital (C) Sam Fazeli, Senior Analyst and European Head, Bloomberg Intelligence (C)</p>
	
17.15	THE NEXT BIG THING? THE IMPENDING ADVANCED THERAPIES REVOLUTION
	<ul style="list-style-type: none"> • Why are we now talking about a commercial inflection point with cell / advanced therapies? • Poised for success in the clinic: how data will define and help separate the hype from hope • Where are we on the route to Pharma acceptance, adoption, interest and investment? • What still needs to be overcome on regulation, reimbursement and pricing? • How does the industry instill confidence in patients, investors, regulators and Pharma? <p>Moderator: Julie Simmonds, Director, Equity Research, Panmure Gordon (C) Keith Thompson, Chief Executive, Cell Therapy Catapult (C) Gbola Amusa, Director of Research Head of Healthcare Research, Chardan Capital Markets (C) Zami Aberman, CEO, Pluristem (C)</p>

17.55	Closing remarks and themed networking drinks reception
-------	--

DAY TWO: 3 February 2016

(All speakers are invited unless labelled as **CONFIRMED**)

8.00	Registration
	
9.00	Chairman Remarks
	KEYNOTE FIRESIDE CHATS
9.15	<p>This session will feature 3-4 fireside chats with prominent UK agencies, associations or initiatives. There are so many wonderful initiatives looking to unlock opportunities and create value for life science companies and Big Pharma in the UK. In this session, we're bringing together the leaders of UK catalysts to update you on what we can expect to see in the next 12 months.</p> <p>Moderator: Adrian Dawkes, Vice President, PharmaVentures (C) Zahid Latif, Head of Healthcare, Innovate UK (C) John Mckinley, CEO, Precision Medicine Catapult (C) Sarah Haywood, CEO, Medcity (C)</p>
	KEYNOTE PANEL: NEW HORIZONS FOR CORPORATE AND BUSINESS DEVELOPMENT
9.45	<ul style="list-style-type: none"> • Are valuations now sufficiently attractive and realistic? • What M&A strategies will create the winners and losers? • With interest rates tightening, and cash being cheap, will we see greater risks being taken in M&A? Are pharma going to be more opportunistic? • Where are the hot areas of activity in M&A? Where will they likely be in the foreseeable future? • How can companies create optimal conditions and opportunities for M&A? • How can integrations deliver value to shareholders? <p>Moderator: Surani Fernando, Editor, EMEA, BioPharm Insight (C) Luigi la Corte, Head of WWBD, GSK (C) Shaun Grady, Vice President, Business Development Operations, AstraZeneca (C) Johnston Erwin, VP, Corporate Business Development, Eli Lilly & Co. (C)</p>

	Corinne Savill , Head, Pharma Business Development & Licensing, Novartis (C)	
10:30	Morning coffee	
		
	DISEASE LEADERSHIP: PHARMA AND BIG BIOTECH PARTNERING AND BD FORUM	ONES TO WATCH: SHOWCASES FROM THE VERY BEST OF UK LIFE SCIENCE COMPANIES
11.00	<p>Over 3.5 hrs of presentations from major Pharma and Big Biotech BD heads showcasing their external partnering and business development opportunities in their areas of disease leadership. Therapeutic areas include Oncology, Cardiovascular and Metabolic, Neuroscience, Inflammation, Infectious Disease, Immunology, Respiratory and Ophthalmic</p> <p>A dedicated room and areas will be available for onsite 1-2-1 meetings along with the 1-2-1 meeting planner 'Meeting Mojo'.</p> <ul style="list-style-type: none"> • Where are the opportunities to work with Pharma? • What are their internal and external R&D approaches and their corporate development partnering strategies? • What are they looking for and why? • What is the best way to work with them? <p>4 Companies to be invited to give 30mins presentations:</p> <p>11.00 Tim Luker, Senior VP, External R&D, Lilly (C)</p> <p>11.30 Nader Halim, Director, CTI, Pfizer (C)</p> <p>12.00 Judith Hills, Senior Vice President Corporate Business Development, Ipsen Biopharm (C)</p> <p>12.30 Susan Herbert, Executive Vice President, Global Business Development and Strategy, Merck KGaA (C)</p>	<p>We showcase presentations from 6 leading British Life Science companies and 6 of the next generation of British Life Science entrepreneurs and their commercial spin-outs.</p> <p>The following companies will be presenting 20mins company showcases:</p> <p>11.00 Eva-Lotta Allan, CBO, Immunocore (C)</p> <p>11.20 Clive Dix, Executive Chairman, C4X Discovery (C)</p> <p>11.40 Robert Habib, CEO, MiNA Therapeutics (C)</p> <p>12.00 David Ribeiro, CEO, ProAxis Ltd. (C)</p> <p>12.20 Keith Martin, CEO, Apitope (C)</p> <p>12.40 Andrew Lightfoot, CEO, Peptinnovate (C)</p>
13.00	Networking lunch	

	Pharma  Forum	UK Ones to Watch 
	DISEASE LEADERSHIP: PHARMA AND BIG BIOTECH PARTNERING AND BD FORUM	ONES TO WATCH: SHOWCASES FROM THE VERY BEST OF UK LIFE SCIENCE COMPANIES
14.00	<p>3 Companies to be invited to give 30mins presentations:</p> <p>14.00 Sarah Holland, Head of Europe, External Science and Partnering, Sanofi (C)</p> <p>14.30 Kay Tait, Transaction Director, Business Development Operations, AstraZeneca (C)</p> <p>15.00 Lubor Gaal, Head of External Innovation and Licensing, Almirall (C)</p>	<p>The following companies will be presenting 15 mins company showcases:</p> <p>14.00 John Normanton, CEO Designate, EstryX (C)</p> <p>14.15 Ian Wilson, CEO, EM Imaging (C)</p> <p>14.30 Nigel Davis, CEO, Medherant (C)</p>
	1-2-1 NETWORKING CLOSING REFRESHMENTS	
15.30	Delegates are invited to close off their networking over a final refreshment break. Lock in those all important final meetings, grab 30mins with a peer or simply grab a coffee before you leave the conference.	
16.00	Close of congress	